Assessment of i-125 prostate implants by tumor bioeffect.
暂无分享,去创建一个
Annette Haworth | Martin Ebert | David Waterhouse | D. Waterhouse | M. Ebert | A. Haworth | David Joseph | G. Duchesne | David Joseph | Gillian Duchesne
[1] J. Fowler,et al. How low is the α/β ratio for prostate cancer? in regard to Wang et al., IJROBP 2003;55:194–203 , 2003 .
[2] C Busch,et al. Modeling prostate cancer distributions. , 1999, Urology.
[3] J. Battista,et al. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer , 2003 .
[4] Michael J. Zelefsky,et al. Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer , 1999 .
[5] C C Ling,et al. Fitting tumor control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: pitfalls in deducing radiobiologic parameters for tumors from clinical data. , 2001, International journal of radiation oncology, biology, physics.
[6] A. Nahum,et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the α/β ratio , 2003 .
[7] W S Bice,et al. Sector analysis of prostate implants. , 2001, Medical physics.
[8] S. Zavgorodni,et al. Modeling dose response in the presence of spatial variations in dose rate. , 2000, Medical physics.
[9] D J Brenner,et al. Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.
[10] A. Nahum,et al. The delta-TCP concept: a clinically useful measure of tumor control probability. , 1999, International journal of radiation oncology, biology, physics.
[11] Warren D. D'Souza,et al. Is the α/β ratio for prostate cancer low? , 2001 .
[12] A. Renshaw,et al. Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated? , 1999, International journal of radiation oncology, biology, physics.
[13] Duchesne Gm,et al. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. , 1999 .
[14] D. Johnston,et al. Detailed mapping of prostate carcinoma foci , 2000, Cancer.
[15] K. Otto,et al. Prostate brachytherapy postimplant dosimetry: a comparison of prostate quadrants. , 2002, International journal of radiation oncology, biology, physics.
[16] R G Dale,et al. Dose-rate effects in targeted radiotherapy. , 1996, Physics in medicine and biology.
[17] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .
[18] T. Stamey,et al. Zonal Distribution of Prostatic Adenocarcinoma: Correlation with Histologic Pattern and Direction of Spread , 1988, The American journal of surgical pathology.
[19] R. Stock,et al. A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.
[20] Jian Z. Wang,et al. Low α/β ratio for prostate cancer: in response to Dr. Fowler et al. , 2003 .
[21] X. Allen Li,et al. HOW LOW IS THE / RATIO FOR PROSTATE CANCER? , 2003 .
[22] Blasko,et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.
[23] C. Mayo,et al. Is the prostate α/β ratio of 1.5 from Brenner & Hall a modeling artifact?1 , 2000 .
[24] D. Brenner,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue , 2002 .
[25] S Webb,et al. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. , 1993, Physics in medicine and biology.
[26] J. Fowler,et al. A simple analytic derivation suggests that prostate cancer α/β ratio is low , 2001 .
[27] Rick Chappell,et al. Is α/β for prostate tumors really low? , 2001 .